Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin J H
Division of Hematologic Oncology, Dana-Farber Cancer Institute, and Harvard School of Public Health, Boston, MA 02115, USA.
J Clin Oncol. 2001 Aug 15;19(16):3685-91. doi: 10.1200/JCO.2001.19.16.3685.
Controversy exists as to whether the incidence of graft-versus-host disease (GVHD) is increased after peripheral-blood stem-cell transplantation (PBSCT) when compared with bone marrow transplantation (BMT). We performed a meta-analysis of all trials comparing the incidence of acute and chronic GVHD after PBSCT and BMT reported as of June, 2000. Secondary analyses examined relapse rates after the two procedures.
An extensive MEDLINE search of the literature was undertaken. Primary authors were contacted for clarification and completion of missing information. A review of cited references was also undertaken. Sixteen studies (five randomized controlled trials and 11 cohort studies) were included in this analysis. Data was extracted by two pairs of reviewers and analyzed for the outcomes of interest. Meta-analyses, regression analyses, and assessments of publication bias were performed.
Using a random effects model, the pooled relative risk (RR) for acute GVHD after PBSCT was 1.16 (95% confidence interval [CI], 1.04 to 1.28; P=.006) when compared with traditional BMT. The pooled RR for chronic GVHD after PBSCT was 1.53 (95% CI, 1.25 to 1.88; P <.001) when compared with BMT. The RR of developing clinically extensive chronic GVHD was 1.66 (95% CI, 1.35 to 2.05; P <.001). The excess risk of chronic GVHD was explained by differences in the T-cell dose delivered with the graft in a meta-regression model that did not reach statistical significance. There was a trend towards a decrease in the rate of relapse after PBSCT (RR = 0.81; 95% CI, 0.62 to 1.05).
Both acute and chronic GVHD are more common after PBSCT than BMT, and this may be associated with lower rates of malignant relapse. The magnitude of the transfused T-cell load may explain the differences in chronic GVHD risk.
外周血干细胞移植(PBSCT)后移植物抗宿主病(GVHD)的发生率与骨髓移植(BMT)相比是否会增加,目前仍存在争议。我们对截至2000年6月报道的所有比较PBSCT和BMT后急性和慢性GVHD发生率的试验进行了荟萃分析。二级分析检测了这两种移植方法后的复发率。
对MEDLINE文献进行广泛检索。联系主要作者以澄清和补充缺失信息。还对引用文献进行了回顾。本分析纳入了16项研究(5项随机对照试验和11项队列研究)。由两对审阅者提取数据并分析感兴趣的结果。进行了荟萃分析、回归分析和发表偏倚评估。
采用随机效应模型,与传统BMT相比,PBSCT后急性GVHD的合并相对风险(RR)为1.16(95%置信区间[CI],1.04至1.28;P = 0.006)。与BMT相比,PBSCT后慢性GVHD 的合并RR为1.53(95% CI,1.25至1.88;P < 0.001)。发生临床广泛慢性GVHD的RR为1.66(95% CI,1.35至2.05;P < 0.001)。在一个未达到统计学显著性的荟萃回归模型中,慢性GVHD的额外风险可由移植物中输送的T细胞剂量差异来解释。PBSCT后复发率有下降趋势(RR = 0.81;95% CI,0.62至1.05)。
PBSCT后急性和慢性GVHD均比BMT更常见,这可能与较低的恶性复发率有关。输注的T细胞负荷量可能解释了慢性GVHD风险的差异。